Gisela Mautner
Follow
Get notifications in MyBN when activity occurs.
Upgrade your subscription to use this feature.
Gisela Mautner
Chief Executive, Managing Director / Noxopharm
Dr Gisela Mautner has pharmaceutical industry experience covering all aspects from clinical research through to product commercialisation.
She has held senior leadership positions at MSD, Bayer and Amgen where she launched several new drugs in different therapeutic areas.
In her early career, Dr Mautner was a clinical scientist at the National Institutes of Health in the USA. Dr Mautner has engaged with the pharmaceutical community and has served on the Executive Committee of APPA (Australian Pharmaceutical Medical and Scientific Professionals Association) for numerous years. She recently handed over her presidency of APPA and continues to serve as past president to promote excellence within the pharmaceutical community.
She has held senior leadership positions at MSD, Bayer and Amgen where she launched several new drugs in different therapeutic areas.
In her early career, Dr Mautner was a clinical scientist at the National Institutes of Health in the USA. Dr Mautner has engaged with the pharmaceutical community and has served on the Executive Committee of APPA (Australian Pharmaceutical Medical and Scientific Professionals Association) for numerous years. She recently handed over her presidency of APPA and continues to serve as past president to promote excellence within the pharmaceutical community.
Lists and Charts
Total Shareholder Return as at 29/02/24
| Rank | Company | 1 yr | 5 yr |
|---|---|---|---|
| 555th | Openpay Group | 7% | 97% |
| 556th | Opyl | 7% | 97% |
| 816th | London City Equities | -6% | 7% |
| 954th | Noxopharm | -15% | -27% |
1790 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®
Powered by Morningstar ®
Roles
Year started and most recent title
Share Transactions
Revenue
| Rank | Company | Revenue | |
|---|---|---|---|
| 842nd |  | Noxopharm | $6.0m |
| 985th | | Cashwerkz | $1.3m |
| 986th | | London City Equities | $1.3m |
| 988th | | Openpay Group | $1.2m |
| 989th | | Opyl | $1.2m |
1330 listed non wa companies ranked by revenue.
Powered by Morningstar ®
Powered by Morningstar ®
Collapse All Lists and Charts
Person Activity
| NEW ROLE: Chief Executive, Managing Director, Noxopharm | 14 Feb 2022 |
